<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027729</url>
  </required_header>
  <id_info>
    <org_study_id>01-078</org_study_id>
    <secondary_id>CDR0000069061</secondary_id>
    <secondary_id>MEDIMMUNE-MI-CP068</secondary_id>
    <secondary_id>NCI-G01-2032</secondary_id>
    <nct_id>NCT00027729</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>Phase I/II Study of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in&#xD;
      treating patients who have advanced colorectal cancer that has not responded to irinotecan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose of monoclonal antibody anti-anb3 integrin in&#xD;
           patients with irinotecan-refractory advanced colorectal cancer.&#xD;
&#xD;
        -  Determine the safety and tolerance of this drug in these patients.&#xD;
&#xD;
        -  Determine any antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the objective response rate, response duration, and time to progression in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive monoclonal antibody anti-anb3 integrin IV over 30 minutes once weekly on&#xD;
      weeks 1-52 in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      responding disease may continue therapy.&#xD;
&#xD;
      Cohort of 4-6 patients receive escalating doses of monoclonal antibody anti-anb3 integrin&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Once the MTD&#xD;
      is determined, additional patients are treated at that dose in the phase II portion of the&#xD;
      study.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-24 patients will be accrued for phase I of this study and a&#xD;
      total of 40 patients will be accrued for phase II of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etaracizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced colorectal cancer&#xD;
&#xD;
          -  Disease progression while receiving an irinotecan-containing regimen for metastatic&#xD;
             colorectal cancer OR&#xD;
&#xD;
          -  Disease recurrence within 6 months after completing an irinotecan-containing regimen&#xD;
             in the adjuvant setting&#xD;
&#xD;
          -  At least 1 measurable lesion (for phase II only)&#xD;
&#xD;
               -  At least 20 mm by x-ray, CT scan, MRI, or photograph&#xD;
&#xD;
               -  Recurrent disease after surgery or radiotherapy is considered measurable if it&#xD;
                  has been at least 4 weeks since treatment and measurable disease is outside the&#xD;
                  port of prior radiotherapy or there is evidence of disease progression within the&#xD;
                  port of prior radiotherapy&#xD;
&#xD;
               -  The following are not considered measurable:&#xD;
&#xD;
                    -  Pleural effusion&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Osteoblastic lesion or evidence of disease on bone scan alone&#xD;
&#xD;
                    -  Progressive irradiated lesions alone&#xD;
&#xD;
                    -  Bone marrow involvement&#xD;
&#xD;
                    -  Brain metastases&#xD;
&#xD;
                    -  Malignant hepatomegaly by physical exam alone&#xD;
&#xD;
                    -  Chemical markers (e.g., carcinoembryonic antigen)&#xD;
&#xD;
          -  No known brain metastases or primary brain tumors&#xD;
&#xD;
          -  No symptomatic pleural effusion or ascites requiring paracentesis&#xD;
&#xD;
          -  No clinical evidence of bowel obstruction&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT/PTT less than ULN OR&#xD;
&#xD;
          -  INR less than 1.12&#xD;
&#xD;
          -  No hepatitis virus infection&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No angina&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg)&#xD;
&#xD;
          -  No prior cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No respiratory insufficiency requiring oxygen treatment&#xD;
&#xD;
          -  No lymphangitic involvement of lungs&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 30 days before, during, and for&#xD;
             30 days after study&#xD;
&#xD;
          -  Thyroxine and thyroid-stimulating hormone normal&#xD;
&#xD;
          -  No hematemesis, melena, hematochezia, or gross hematuria&#xD;
&#xD;
          -  No prior significant adverse reaction to a humanized monoclonal antibody&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No active infection requiring systemic anti-infective therapy&#xD;
&#xD;
          -  No other medical or psychological condition or behavior, including substance&#xD;
             dependence or abuse, that would preclude study&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer or&#xD;
             completely excised carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior immunotherapy with approved agents allowed&#xD;
&#xD;
          -  No prior monoclonal antibody anti-anb3 integrin or its precursor (MEDI-523)&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent palliative chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery and surgical wounds must have healed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard B. Saltz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

